{"nct_id":"NCT06989112","title":"DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer","status":"RECRUITING","status_verified_date":"2025-09","start_date":"2025-03-27","start_date_type":"ACTUAL","primary_completion_date":"2029-01-19","primary_completion_date_type":"ESTIMATED","completion_date":"2031-02-19","completion_date_type":"ESTIMATED","phases":["PHASE3"],"tickers":["AZN"]}